TargetMol

JR-AB2-011

Product Code:
 
TAR-T11728
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T11728-1mg1mg£164.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11728-5mg5mg£298.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11728-1mL1 mL * 10 mM (in DMSO)£306.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11728-10mg10mg£407.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11728-25mg25mg£630.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11728-50mg50mg£870.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11728-100mg100mg£1,139.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
JR-AB2-011 inhibits mTORC2 activity by blocking Rictor-mTOR association (Ki: 0.19 μM). JR-AB2-011 has anti-glioblastoma multiforme (GBM) properties. JR-AB2-011 is a selective mTORC2 inhibitor with an IC50 value of 0.36 μM.
CAS:
329182-61-8
Formula:
C17H14Cl2FN3OS
Molecular Weight:
398.28
Pathway:
PI3K/Akt/mTOR signaling
Purity:
0.9887
SMILES:
CC1CN=C(S1)N(C(=O)Nc1ccc(Cl)c(Cl)c1)c1ccc(F)cc1
Target:
mTOR

References

1. Benavides-Serrato A, et al. Correction: Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxicin glioblastoma. PLoS One. 2019 Feb 6;14(2):e0212160.